Novartis – science based innovation for better patient outcomes

Primary tabs

Novartis – science based innovation for better patient outcomes

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Content from this campaign

Asian Malaria Endgame Threatened by Resistance to Insecticides and Malaria Treatments
Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas Elimination will also depend on...
Apr 23, 2019 7:00 AM ET
Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug
The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture. The grant will...
Apr 15, 2019 3:00 AM ET
Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America;...
Mar 14, 2019 12:45 PM ET
Novartis Announces Five Grant Recipients of Excellence in Ophthalmology Vision Award (Xova) for Nonprofit Sustainable Eye Health Initiatives
A panel of independent ophthalmologists and optometrists selected five winners out of more than 100 entries from 34 countries  The 2018 grants support initiatives ranging from training teachers for vision screening in schools to launching eye care-specific training modules in Ethiopia, India, Micronesia, Sudan and Zimbabwe  Novartis has...
Sep 24, 2018 4:20 PM ET
Novartis Renews Drug Donation of Egaten® (Triclabendazole) Until 2022, Reaffirming Its Commitment to the Fight Against Liver Fluke
Novartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million people globally1 Since the start of the donation program in 2005, Novartis has donated approximately 4 million tablets of Egaten, valued at...
Jul 23, 2018 12:00 PM ET

Pages